← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Makscientific, Llc
W. Mystic, CT
$5,297,483
Total funding
12
Grants
Funding over time
peak $1.2M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,297,483 · 12
By mechanism
R44$2,871,069 · 3
R43$1,113,560 · 5
N44$750,000 · 1
R41$224,999 · 1
U18$218,855 · 1
N43$119,000 · 1
Investigators at Makscientific, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
NOVEL AZETIDINE CB1 ANTAGONISTS$726,174
N44 · FY2009 · DA
NAAA Inhibitors as Anti-inflammatory Agents, Phase II$646,219
R44 · FY2017 · DK
NAAA Inhibitors as Anti-inflammatory Agents, Phase II$646,219
R44 · FY2016 · DK
A CB1 Antagonist for Treatment of Kidney Disease$572,743
R44 · FY2024 · DK
New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase$516,628
R44 · FY2011 · DA
New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase$489,260
R44 · FY2009 · DA
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).$320,000
R43 · FY2023 · DA
NAAA Inhibitors as Anti-Inflammatory Agents$232,633
R43 · FY2015 · DK
Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases$224,999
R41 · FY2019 · DK
Cannabinergic Receptor Antagonists for Nicotine Addiction$221,844
R43 · FY2014 · DA
Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD)$218,855
U18 · FY2020 · DA
CB1 Receptor Antagonists in Drug Abuse$154,017
R43 · FY2004 · DA
New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity$130,066
R43 · FY2007 · DA
Novel Azetidine CB1 Antagonists$119,000
N43 · FY2008 · DA
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).$55,000
R43 · FY2025 · DA
NOVEL AZETIDINE CB1 ANTAGONISTS$23,826
N44 · FY2010 · DA